Chinook Therapeutics, Inc. Common Stock
KDNY
KDNY was delisted on the 10th of August, 2023.
105 hedge funds and large institutions have $727M invested in Chinook Therapeutics, Inc. Common Stock in 2022 Q1 according to their latest regulatory filings, with 14 funds opening new positions, 39 increasing their positions, 32 reducing their positions, and 12 closing their positions.
400% more call options, than puts
Call options by funds: $1.02M | Put options by funds: $204K
75% more funds holding in top 10
Funds holding in top 10: 4 → 7 (+3)
22% more repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 32
17% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 12
2% more funds holding
Funds holding: 103 → 105 (+2)
3% more capital invested
Capital invested by funds: $707M → $727M (+$20.3M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$14.1M |
| 2 |
OCA
Octagon Capital Advisors
New York
|
+$11.6M |
| 3 |
EC
EcoR1 Capital
San Francisco,
California
|
+$9.38M |
| 4 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$7.88M |
| 5 |
Millennium Management
New York
|
+$5.26M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FM
Frazier Management
Seattle,
Washington
|
-$38.7M |
| 2 |
BI
BVF Inc
San Francisco,
California
|
-$29.4M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$14.9M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$6.07M |
| 5 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
-$4.87M |
KDNY Hedge Fund Activity: Q1 2022 in Review
105 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Chinook Therapeutics, Inc. Common Stock (KDNY) for Q1 2022, worth a combined $727M — up 2.9% from $707M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new KDNY positions and 12 closed out — a net gain of 2 holders — while 39 added to existing stakes and 32 trimmed.
The largest buyer was Great Point Partners, adding an estimated $14.1M. The largest seller was Frazier Management, exiting entirely with an estimated $38.7M sold.
- 105 institutional investors held Chinook Therapeutics, Inc. Common Stock (KDNY) as of Q1 2022, up from 103 in Q4 2021.
- Funds reported $727M of Chinook Therapeutics, Inc. Common Stock stock for Q1 2022, up 2.9% quarter-over-quarter.
- 14 funds opened new Chinook Therapeutics, Inc. Common Stock positions in Q1 2022 and 12 closed out, a net change of +2 holders.
- The largest Chinook Therapeutics, Inc. Common Stock buyer in Q1 2022 was Great Point Partners, an estimated $14.1M added.
- The largest Chinook Therapeutics, Inc. Common Stock seller in Q1 2022 was Frazier Management, an estimated $38.7M sold.
Based on aggregated 13F filings for Q1 2022.